PR
IMNM icon

PSP Research’s Immunome IMNM Stock Holding History

PSP Research’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$381K Sell
18,000
-2,000
-10% -$42.8K 0.2% 38
2026
Q1 		$437K Sell
20,000
-5,245
-21% -$117K 0.31% 41
2025
Q4 		$542K Buy
+25,245
New +$443K 0.47% 19

Other funds holding IMNM

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return

PSP Research's IMNM Position: Q2 2026 in Review

PSP Research reduced its Immunome (IMNM) stake by 10% in Q2 2026, selling an estimated $42.8K and leaving 18,000 shares worth $381K. The position accounts for 0.2% of the portfolio, ranked #38.

PSP Research first reported a position in IMNM in Q4 2025 and has held it in 3 quarters since. The position peaked at $542K in Q4 2025. 202 funds tracked by Wall St. Rank hold IMNM as of Q2 2026.

  • PSP Research held 18,000 shares of Immunome worth $381K as of Q2 2026.
  • PSP Research sold 2,000 Immunome shares in Q2 2026, an estimated $42.8K.
  • Immunome made up 0.2% of PSP Research's portfolio in Q2 2026, its #38 holding.
  • PSP Research first reported a position in Immunome in Q4 2025 and has held it in 3 quarters since.
  • PSP Research's Immunome position peaked at $542K in Q4 2025.
  • 202 funds tracked by Wall St. Rank held Immunome as of Q2 2026.

Based on PSP Research's 13F filing for Q2 2026, filed 9 Jul 2026.